文献速递类风湿关节炎

乌帕替尼对比阿达木单抗治疗类风湿关节炎的7年长期安全性与疗效:SELECT-COMPARE研究

Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study.
PubMed 文献 · RMD Open · 2026-06-24

SELECT-COMPARE研究评估乌帕替尼15 mg每日一次对比阿达木单抗40 mg隔周一次(均联合甲氨蝶呤)治疗甲氨蝶呤反应不佳的类风湿关节炎患者,随访至7年。乌帕替尼总体耐受性良好,不良事件发生率与阿达木单抗相当,但带状疱疹、肌酸磷酸激酶升高、非黑色素瘤皮肤癌、淋巴细胞减少和肝脏疾病发生率数值上更高。两药持续或挽救治疗均可维持疾病活动度目标至372周,乌帕替尼组达到临床疾病活动指数缓解和基于C反应蛋白的28关节疾病活动度评分<2.6的比例在观察分析中高于阿达木单抗。

要点

  • 乌帕替尼7年安全性总体与既往分析一致,未发现新安全信号
  • 带状疱疹、肌酸磷酸激酶升高、非黑色素瘤皮肤癌等发生率数值上高于阿达木单抗
  • 持续或挽救治疗均可维持疾病活动度目标至7年

核心结论

  • 乌帕替尼治疗类风湿关节炎7年安全性特征与既往分析一致,无新安全担忧,获益风险比可接受。
  • 乌帕替尼与阿达木单抗持续或挽救治疗均可维持疾病活动度目标至7年。

研究设计与样本

  • SELECT-COMPARE研究为正在进行的随机对照研究,类风湿关节炎且对甲氨蝶呤反应不佳患者随机接受安慰剂、乌帕替尼15 mg每日一次或阿达木单抗40 mg隔周一次(背景甲氨蝶呤)。
  • 应答不佳者挽救至替代治疗,安慰剂组于第26周前切换至乌帕替尼,完成48周者进入10年延伸期。
  • 安全性以治疗中出现的不良事件评估,疗效按随机分组(无应答者填补)或治疗序列(观察分析)分析。

主要发现

  • 乌帕替尼总体耐受性良好,治疗中出现的不良事件发生率与阿达木单抗相当,但带状疱疹、肌酸磷酸激酶升高、非黑色素瘤皮肤癌、淋巴细胞减少和肝脏疾病发生率数值上更高。
  • 持续乌帕替尼或阿达木单抗的应答维持至372周;第372周乌帕替尼组临床疾病活动指数缓解(≤2.8)和基于C反应蛋白的28关节疾病活动度评分<2.6在观察分析中分别为145/230(63.0%)和178/204(83.2%),无应答者填补分析中分别为142/651(21.8%)和172/651(26.4%)。
  • 第372周阿达木单抗组上述缓解在观察分析中分别为46/86(53.5%)和59/81(72.8%),无应答者填补分析中分别为43/327(13.1%)和55/327(16.8%)。
  • 初始无应答者/不完全应答者从切换中获益,切换后疗效终点改善维持至第336周,无额外安全担忧。

关键数值与推荐

  • 第372周乌帕替尼组临床疾病活动指数缓解(≤2.8)观察分析为145/230(63.0%),无应答者填补分析为142/651(21.8%)。
  • 第372周乌帕替尼组基于C反应蛋白的28关节疾病活动度评分<2.6观察分析为178/204(83.2%),无应答者填补分析为172/651(26.4%)。
  • 第372周阿达木单抗组临床疾病活动指数缓解(≤2.8)观察分析为46/86(53.5%),无应答者填补分析为43/327(13.1%)。
  • 第372周阿达木单抗组基于C反应蛋白的28关节疾病活动度评分<2.6观察分析为59/81(72.8%),无应答者填补分析为55/327(16.8%)。

临床怎么用

  • 乌帕替尼可作为甲氨蝶呤反应不佳的类风湿关节炎患者长期治疗选择之一,需关注带状疱疹、肌酸磷酸激酶升高、非黑色素瘤皮肤癌、淋巴细胞减少和肝脏疾病等事件。
  • 治疗过程中应定期监测上述不良事件相关指标,并根据疾病活动度评估持续或调整治疗。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the safety and efficacy of upadacitinib versus adalimumab through 7 years in the ongoing SELECT-COMPARE study. METHODS: Patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX) were randomised to placebo, upadacitinib 15 mg once daily or adalimumab 40 mg every other week (on background MTX). Inadequate responders were rescued to the alternate therapy, with placebo recipients switching to upadacitinib by week 26. Patients completing 48 weeks were eligible to enter the 10-year extension. Safety was assessed as treatment-emergent adverse events (TEAEs); efficacy was analysed by randomised group (non-responder imputation [NRI]) or treatment sequence (as observed [AO]). RESULTS: Upadacitinib was generally well tolerated, displaying TEAE rates comparable to adalimumab, but numerically higher rates of herpes zoster, creatine phosphokinase elevation, non-melanoma skin cancer, lymphopenia and hepatic disorders. Responses with continuous upadacitinib or adalimumab were maintained through 372 weeks; week 372 Clinical Disease Activity Index remission (≤2.8) and 28-joint Disease Activity Score based on C-reactive protein<2.6 were achieved by 145/230 (63.0%) and 178/204 (83.2%) (AO)/142/651 (21.8%) and 172/651 (26.4%) (NRI) of patients with upadacitinib versus 46/86 (53.5%) and 59/81 (72.8%) (AO)/43/327 (13.1%) and 55/327 (16.8%) (NRI) with adalimumab. Initial non-responders/incomplete responders benefited from switching, with improvements in efficacy endpoints maintained through week 336 post switch, without additional safety concerns. CONCLUSION: The safety profile of upadacitinib remained consistent with previous analyses, with no new safety concerns through 7 years. Upadacitinib and adalimumab (continuous or rescue treatment) maintained disease activity targets throughout the 7-year treatment period. Upadacitinib exhibited an acceptable benefit-risk profile for long-term RA treatment. TRIAL REGISTRATION NUMBER: NCT02629159.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Fleischmann R, Swierkot J, Durez P, et al. Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study. RMD Open. 2026. PMID: 42342288. doi:10.1136/rmdopen-2025-006657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。